Alyeska Investment Group
IONS icon

Alyeska Investment Group’s Ionis Pharmaceuticals IONS Stock Holding History

Alyeska Investment Group’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$112M Buy
1,417,916
+944,766
+200% +$71.1M 0.29% 82
2026
Q1 		$35.5M Sell
473,150
-8,561
-2% -$676K 0.1% 229
2025
Q4 		$38.1M Buy
481,711
+170,453
+55% +$12.8M 0.11% 228
2025
Q3 		$20.4M Buy
311,258
+152,250
+96% +$7.43M 0.06% 282
2025
Q2 		$6.28M Buy
+159,008
New +$5.2M 0.02% 397
2025
Q1 		– Sell
-150,000
Closed -$5.24M – 582
2024
Q4 		$5.24M Sell
150,000
-18,951
-11% -$708K 0.02% 396
2024
Q3 		$6.77M Buy
+168,951
New +$7.86M 0.03% 324
2021
Q2 		– Sell
-427,990
Closed -$19.2M – 779
2021
Q1 		$19.2M Buy
427,990
+225,513
+111% +$12.6M 0.25% 126
2020
Q4 		$11.4M Buy
+202,477
New +$10.1M 0.16% 176

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Alyeska Investment Group's IONS Position: Q2 2026 in Review

Alyeska Investment Group increased its Ionis Pharmaceuticals (IONS) stake by 200% in Q2 2026, buying an estimated $71.1M and bringing the position to 1,417,916 shares worth $112M. The position accounts for 0.29% of the portfolio, ranked #82.

Alyeska Investment Group first reported a position in IONS in Q4 2020 and has held it in 9 quarters since. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Alyeska Investment Group held 1,417,916 shares of Ionis Pharmaceuticals worth $112M as of Q2 2026.
  • Alyeska Investment Group bought 944,766 Ionis Pharmaceuticals shares in Q2 2026, an estimated $71.1M.
  • Ionis Pharmaceuticals made up 0.29% of Alyeska Investment Group's portfolio in Q2 2026, its #82 holding.
  • Alyeska Investment Group first reported a position in Ionis Pharmaceuticals in Q4 2020 and has held it in 9 quarters since.
  • 514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.